Evelyn M Wong1, Anna Lehman2, Philip Acott3, Jane Gillis4, Daniel L Metzger5, Sandra Sirrs6,7. 1. Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 2. Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 3. Department of Pediatrics and Department of Pharmacology, Dalhousie University, Halifax, NS, Canada. 4. Division of Biochemical Disease, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 5. Division of Pediatric Endocrinology, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 6. Division of Endocrinology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada. Sandra.Sirrs@vch.ca. 7. Gordon and Leslie Diamond Centre, Adult Metabolic Diseases Clinic, 2775 Laurel St., Level 4, Vancouver, BC, Canada, V5Z 1M9. Sandra.Sirrs@vch.ca.
Abstract
BACKGROUND: Glycogen storage disease type 1 is an autosomal recessive disorder with an incidence of 1 in 100,000. Long-term complications include chronic blood glucose lability, lactic academia, short stature, osteoporosis, delayed puberty, gout, progressive renal insufficiency, systemic or pulmonary hypertension, hepatic adenomas at risk for malignant transformation, anemia, vitamin D deficiency, hyperuricemic nephrocalcinosis, inflammatory bowel syndrome (type 1b), hypertriglyceridemia, and irregular menstrual cycles. We describe hypogonadotropic hypogonadism as a novel complication in glycogen storage disease (GSD) type 1. Case Studies and Methods: Four unrelated patients with GSD 1a (N = 1) and 1b (N = 3) were found to have hypogonadotropic hypogonadism diagnosed at different ages. Institutional Research Ethics Board approval was obtained as appropriate. Participant consent was obtained. A retrospective chart review was performed and clinical symptoms and results of investigations summarized as a case series. RESULTS: All patients were confirmed biochemically to have low luteinizing hormone (LH) and follicular stimulating hormone (FSH), and correspondingly low total testosterone. Clinical symptoms of hypogonadism varied widely. Investigations for other causes of hypogonadotropic hypogonadism were unremarkable. In addition, all patients were found to have disproportionately low bone mineral density at the lumbar spine compared to the hip. Common to all patients was erratic metabolic control, including recurrent hypoglycemia and elevated lactate levels. DISCUSSION: Recurrent elevations in cortisol in response to hypoglycemia may be the underlying pathology leading to suppression of gonadotropin-releasing hormone (GnRH) release. Incorporating clinical and/or biochemical screening of the hypothalamic-pituitary-gonadal axis may be important in the management of this disease. Testosterone therapy however needs to be carefully considered because of the risk of hepatic adenomas.
BACKGROUND: Glycogen storage disease type 1 is an autosomal recessive disorder with an incidence of 1 in 100,000. Long-term complications include chronic blood glucose lability, lactic academia, short stature, osteoporosis, delayed puberty, gout, progressive renal insufficiency, systemic or pulmonary hypertension, hepatic adenomas at risk for malignant transformation, anemia, vitamin D deficiency, hyperuricemic nephrocalcinosis, inflammatory bowel syndrome (type 1b), hypertriglyceridemia, and irregular menstrual cycles. We describe hypogonadotropic hypogonadism as a novel complication in glycogen storage disease (GSD) type 1. Case Studies and Methods: Four unrelated patients with GSD 1a (N = 1) and 1b (N = 3) were found to have hypogonadotropic hypogonadism diagnosed at different ages. Institutional Research Ethics Board approval was obtained as appropriate. Participant consent was obtained. A retrospective chart review was performed and clinical symptoms and results of investigations summarized as a case series. RESULTS: All patients were confirmed biochemically to have low luteinizing hormone (LH) and follicular stimulating hormone (FSH), and correspondingly low total testosterone. Clinical symptoms of hypogonadism varied widely. Investigations for other causes of hypogonadotropic hypogonadism were unremarkable. In addition, all patients were found to have disproportionately low bone mineral density at the lumbar spine compared to the hip. Common to all patients was erratic metabolic control, including recurrent hypoglycemia and elevated lactate levels. DISCUSSION: Recurrent elevations in cortisol in response to hypoglycemia may be the underlying pathology leading to suppression of gonadotropin-releasing hormone (GnRH) release. Incorporating clinical and/or biochemical screening of the hypothalamic-pituitary-gonadal axis may be important in the management of this disease. Testosterone therapy however needs to be carefully considered because of the risk of hepatic adenomas.
Entities:
Keywords:
Glycogen storage disease type I; Hypoglycemia; Hypogonadotropic hypogonadism; Male hypogonadism; Metabolic bone disease; Testosterone
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: V Bousson; A Meunier; C Bergot; E Vicaut; M A Rocha; M H Morais; A M Laval-Jeantet; J D Laredo Journal: J Bone Miner Res Date: 2001-07 Impact factor: 6.741
Authors: Giovanni Corona; Elisa Maseroli; Giulia Rastrelli; Andrea M Isidori; Alessandra Sforza; Edoardo Mannucci; Mario Maggi Journal: Expert Opin Drug Saf Date: 2014-08-19 Impact factor: 4.250
Authors: María-José de Castro; Paula Sánchez-Pintos; Nisreem Abdelaziz-Salem; Rosaura Leis; María L Couce Journal: Nutrients Date: 2021-06-20 Impact factor: 5.717